Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Spruce Biosciences Inc is a biotechnology business based in the US. Spruce Biosciences Inc shares (SPRB) are listed on the NASDAQ and all prices are listed in US Dollars. Spruce Biosciences Inc employs 16 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $1.66 |
|---|---|
| 52-week range | $1.25 - $11.51 |
| 50-day moving average | $1.66 |
| 200-day moving average | $3.11 |
| Wall St. target price | $9.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.89 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.66 from 2022-06-24
| 1 week (2022-06-16) | 13.70% |
|---|---|
| 1 month (2022-05-25) | 25.76% |
| 3 months (2022-03-22) | N/A |
| 6 months (2021-12-23) | -55.38% |
| 1 year (2021-06-25) | -84.91% |
|---|---|
| 2 years (2020-06-22) | N/A |
| 3 years (2019-06-22) | N/A |
| 5 years (2017-06-22) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -20.44% |
| Return on equity TTM | -36.66% |
| Profit margin | 0% |
| Book value | $4.27 |
| Market capitalisation | $42.8 million |
TTM: trailing 12 months
We're not expecting Spruce Biosciences Inc to pay a dividend over the next 12 months.
Spruce Biosciences, Inc. , a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Everything we know about the NYIAX IPO, plus information on how to buy in.
Everything we know about the Adamas One Corp IPO, plus information on how to buy in.
Everything we know about the Glucose Health IPO, plus information on how to buy in.
Everything we know about the Boustead Wavefront IPO, plus information on how to buy in.
Everything we know about the ParaZero Technologies IPO, plus information on how to buy in.
